EUVIMEDEUVIMED entdecken
Crossref

Enhancing therapeutic efficacy of fingolimod via intranasal delivery in an ethidium bromide-induced model of multiple sclerosis

Anshul Sharma, Nitin Sharma, Kushagra Khanna, Akshita Arora, Sidharth Mehan, Anjana Sharma

Journal of Neuroscience Methods · 2025-06 · 418 · 110415

DOI: 10.1016/j.jneumeth.2025.110415 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neuroscience Methods, 2025-06. Verfasst von Anshul Sharma und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, ISF College of Pharmacy, Ferozepur GT Road, Moga, Punjab 142001, India. Hauptthemen laut MEDLINE: Fingolimod Hydrochloride, Multiple Sclerosis, Immunosuppressive Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Israel Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Multiple sclerosis (MS) is a chronic inflammatory autoimmune neurological characterized by muscle weakness, numbness, tingling, vision problems, and difficulty in coordination and balance caused by the damage of myelin content around the nerve fibres. The recent literature is evident that along with their lymphocyte attack prevention mechanism, fingolimod (FNG) can serve as neuroprotective also by ensuring their improved brain availability. Therefore, in this project brain availability of FNG was enhanced by delivering the FNG in the form of nanoparticles. NEW METHODS: Fingolimod-loaded solid lipid nanoparticles (FNG-SLNs) were prepared using the solvent evaporation method and formulation factors (lipid concentration; X1, speed; X2, surfactant concentration; X3) and response were established by factorial design. FNG-SLNs were characterized for particle size, entrapment efficiency and in-vitro drug release. Optimized formulations were characterized for in-vivo efficacy study in ethidium bromide-induced MS rat model. RESULT: Obtained data revealed that the particle size and entrapment efficiency of FNG-SLNs optimized formulation was 125.4 nm and 79.86 % w/w respectively. In-vitro drug release study showed an initial burst release of the FNG up to 32.52 % in 30 min followed by sustained drug release up to 78.22 % in 24 h. Furthermore, in-vivo data of FNG-SLNs on ethidium bromide-induced MS rat model revealed better treatment response by showing several evidence such as signs of remyelination, restoration of neuron shape, and the recovered oligodendrocytes. COMPARISON WITH EXISTING METHODS: To the best of our knowledge this article demonstrates improved efficacy of FNG using SLNs. CONCLUSION: This study demonstrates the successful development of FNG-SLNs to enhance the therapeutic efficacy of FNG for the treatment of multiple sclerosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fingolimod HydrochlorideMultiple SclerosisImmunosuppressive AgentsAnimalsAdministration, IntranasalDisease Models, AnimalRatsEthidiumNanoparticlesFemaleParticle SizeRats, WistarMaleBrain

Stichwörter der Autor:innen

Multiple sclerosisethidium bromidefingolimodmyelinnanomedicinesolid lipid nanoparticles

Substanzen

Fingolimod HydrochlorideEthidiumImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Pharmaceutics, ISF College of Pharmacy, Ferozepur GT Road, Moga, Punjab 142001, India.
  • Department of Pharmaceutics, ISF College of Pharmacy, Ferozepur GT Road, Moga, Punjab 142001, India; Department of Pharmaceutics, Amity Institute of Pharmacy, Amity University, Sector-125, Noida, Uttar Pradesh 201313, I…
  • Faculty of Pharmaceutical Sciences, UCSI University, Kuala Lumpur 56000, Malaysia.
  • Department of Pharmacology, ISF College of Pharmacy, Ferozepur GT Road, Moga, Punjab 142001, India.
  • Lloyd Institute of Management & Technology, Plot No -11, Knowledge Park-II, Greater Noida, Uttar Pradesh 201306, India.

Förderung

  • Israel Science Foundation

Zitieren

APA

Sharma, A., Sharma, N., Khanna, K., Arora, A., Mehan, S., & Sharma, A. (2025). Enhancing therapeutic efficacy of fingolimod via intranasal delivery in an ethidium bromide-induced model of multiple sclerosis. Journal of Neuroscience Methods, 418, 110415. https://doi.org/10.1016/j.jneumeth.2025.110415

Vancouver

Sharma A, Sharma N, Khanna K, Arora A, Mehan S, Sharma A. Enhancing therapeutic efficacy of fingolimod via intranasal delivery in an ethidium bromide-induced model of multiple sclerosis. Journal of Neuroscience Methods. 2025;418:110415. doi:10.1016/j.jneumeth.2025.110415

BibTeX
@article{Sharma2025,
  author = {Sharma, Anshul and Sharma, Nitin and Khanna, Kushagra and Arora, Akshita and Mehan, Sidharth and Sharma, Anjana},
  title = {Enhancing therapeutic efficacy of fingolimod via intranasal delivery in an ethidium bromide-induced model of multiple sclerosis},
  journal = {Journal of Neuroscience Methods},
  year = {2025},
  volume = {418},
  pages = {110415},
  doi = {10.1016/j.jneumeth.2025.110415}
}
Kostenlos starten →